Cerebral Amyloid Angiopathy Is Associated With Higher R 2 Relaxation Rate: An MRI and Pathology Study
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Md Tahmid Yasar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Magnetic Resonance Imaging, Brain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute on Aging.
Abstract (Originalsprache)
Objective
Cerebral amyloid angiopathy (CAA) involves β‐amyloid deposition in the walls of cortical and leptomeningeal small vessels. Transverse relaxation rate (R 2 ) is a major source of contrast in MRI. This study tested the hypothesis that CAA is associated with R 2 , extracted the spatial pattern of CAA‐related R 2 abnormalities, and evaluated R 2 at different CAA severity levels in a large number of community‐based older adults.
Methods
Cerebral hemispheres from 804 older adults who came to autopsy were included. All hemispheres underwent ex vivo MRI and detailed neuropathologic examination. R 2 maps were generated from ex vivo MRI data. Voxel‐wise and region‐based regression analyses were conducted to investigate the association of R 2 with CAA, controlling for other neuropathologies and demographics. R 2 values at different CAA severity levels were also investigated.
Results
CAA severity was associated with a higher transverse relaxation rate R 2 in cortical and juxtacortical frontal and medial temporal lobe regions, and in deep brain structures, independently of other neuropathologies and demographics. R 2 abnormalities were significant in severe CAA, but were limited in terms of spatial extent and magnitude in moderate CAA, and were not detectable in mild CAA.
Interpretation
This is to our knowledge the first investigation of the link between CAA and R 2 , one of the major contrast mechanisms in MRI. R 2 is sensitive to CAA‐related brain abnormalities, primarily in moderate and severe stages of the disease. In vivo detection of CAA is an important challenge, and the present work contributes new knowledge that may aid toward this goal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, USA.
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Pathology, Rush University Medical Center, Chicago, Illinois, USA.
- Department of Diagnostic Radiology, Rush University Medical Center, Chicago, Illinois, USA.
ORCID-Profile: Konstantinos Arfanakis
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Yasar, M. T., Evia, A. M., Tazwar, M., Leurgans, S. E., Bennett, D. A., Schneider, J. A., & Arfanakis, K. (2025). Cerebral Amyloid Angiopathy Is Associated With Higher R 2 Relaxation Rate: An MRI and Pathology Study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70037
Vancouver
Yasar MT, Evia AM, Tazwar M, Leurgans SE, Bennett DA, Schneider JA, et al. Cerebral Amyloid Angiopathy Is Associated With Higher R 2 Relaxation Rate: An MRI and Pathology Study. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70037
BibTeX
@article{Yasar2025,
author = {Yasar, Md Tahmid and Evia, Arnold M and Tazwar, Mahir and Leurgans, Sue E and Bennett, David A and Schneider, Julie A and Arfanakis, Konstantinos},
title = {Cerebral Amyloid Angiopathy Is Associated With Higher R 2 Relaxation Rate: An MRI and Pathology Study},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70037}
}
EUVIMED